文献速递心脑血管急症

急诊科静脉地尔硫䓬持续输注治疗快速型心房颤动或心房扑动:一项回顾性探索性分析

Intravenous diltiazem infusions for rapid atrial fibrillation or flutter in the emergency department: A retrospective, exploratory analysis.
PubMed 文献 · Acad Emerg Med · 2024-07-27
一句话结论急诊房颤/房扑快速心室率患者,地尔硫䓬推注后加用持续输注与急诊心率控制率更低相关(OR 0.69,95%CI 0.48-0.99),住院时间延长22.5小时。

本研究为单中心回顾性队列研究,纳入2020年1月1日至2022年11月8日急诊心房颤动或心房扑动且心率>100次/分的患者746例,其中382例(51.2%)在静脉地尔硫䓬推注后接受地尔硫䓬持续输注,364例(48.8%)未接受输注。未校正分析中,输注组急诊末次心率<100次/分的比例为55.2%,未输注组为65.9%(差值10.7%,95%CI 3.7-17.7)。倾向性评分匹配后,地尔硫䓬输注与急诊心率控制可能性更低相关(OR 0.69,95%CI 0.48-0.99),且住院时间延长22.5小时(95%CI 12.2-36.8)。作者结论认为,对于心房颤动或心房扑动患者,静脉地尔硫䓬推注后使用持续输注与急诊心率控制更差相关。

要点

  • 单中心回顾性队列纳入746例急诊房颤/房扑且心率>100次/分患者,382例(51.2%)推注地尔硫䓬后接受持续输注,364例(48.8%)未接受。
  • 未校正分析:输注组急诊末次心率<100次/分比例55.2%,未输注组65.9%(差值10.7%,95%CI 3.7-17.7)。
  • 倾向性评分匹配后,地尔硫䓬输注与急诊心率控制可能性更低相关(OR 0.69,95%CI 0.48-0.99)。
  • 匹配后地尔硫䓬输注组住院时间较未输注组延长22.5小时(95%CI 12.2-36.8)。

适用人群与场景

  • 单中心医院系统急诊科的心房颤动(AF)或心房扑动(AFL)且心率(HR)>100次/分的患者,在静脉地尔硫䓬推注后接受或不接受地尔硫䓬持续输注。

诊断标准与关键阈值

  • 纳入标准:急诊心房颤动或心房扑动,心率>100次/分,接受静脉地尔硫䓬推注。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究,倾向性评分匹配比较。
  • 样本量:746例心房颤动或心房扑动患者纳入分析,其中382例(51.2%)接受地尔硫䓬持续输注,364例(48.8%)未接受。
  • 主要终点(急诊离院时心率<100次/分):未校正分析中,输注组55.2% vs 未输注组65.9%(差值10.7%,95%CI 3.7-17.7)。
  • 倾向性评分匹配后,地尔硫䓬输注与急诊心率控制可能性更低相关(OR 0.69,95%CI 0.48-0.99)。
  • 倾向性评分匹配后,地尔硫䓬输注组住院时间较未输注组延长22.5小时(95%CI 12.2-36.8)。
  • 次要终点包括住院时间及安全性(低血压、电复律、血管升压药使用和死亡),摘要未报告具体安全性结果。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究(探索性分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对于心房颤动或心房扑动患者,静脉地尔硫䓬推注后使用持续输注与急诊心率控制更差相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Emergency physicians commonly treat patients with atrial fibrillation (AF) or atrial flutter (AFL) with rapid ventricular response, and intravenous (IV) diltiazem is the most commonly used medication for rate control of such patients. We sought to compare rate control success and safety outcomes for emergency department (ED) patients with AF or AFL who, after a diltiazem bolus, received a diltiazem drip compared to those who did not receive a drip.

METHODS: We performed a retrospective cohort study comparing outcomes of ED patients from a single hospital system with AF and AFL and a heart rate (HR) > 100 beats/min who received a diltiazem drip after an IV diltiazem bolus to those who received no drip. The primary outcome was a HR < 100 beats/min at the time of ED disposition. Secondary outcomes were hospital length of stay and safety (hypotension, electrical cardioversion, vasopressor use, and death). We compared groups using propensity score matching.

RESULTS: Between January 1, 2020, and November 8, 2022, there were 746 AF or AFL patients eligible for analysis. Of those, 382 (51.2%) received a diltiazem drip and 364 (48.8%) did not. In the unadjusted analysis, the last recorded ED HR was <100 beats/min in 55.2% of patients in the drip group compared to 65.9% in the no-drip group (difference 10.7%, 95% confidence interval [CI] 3.7 to 17.7). After propensity matching, diltiazem drip use was associated with lower likelihood of rate control in the ED (OR 0.69, 95% CI 0.48-0.99) and 22.5 h (95% CI 12.2-36.8) longer hospital stay.

CONCLUSIONS: For patients with AF or AFL, the use of a diltiazem drip after an IV diltiazem bolus was associated with less rate control in the ED.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zitek T, Pagano K, Fernandez C, et al. Intravenous diltiazem infusions for rapid atrial fibrillation or flutter in the emergency department: A retrospective, exploratory analysis. Acad Emerg Med. 2024. PMID: 39072831. doi:10.1111/acem.14989

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。